Nicholas Baxter - Jul 26, 2024 Form 4 Insider Report for Lexaria Bioscience Corp. (LEXX)

Role
Director
Signature
/Nicholas Baxter/
Stock symbol
LEXX
Transactions as of
Jul 26, 2024
Transactions value $
$0
Form type
4
Date filed
7/30/2024, 11:25 AM
Previous filing
May 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding LEXX common shares 11K Jul 26, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LEXX Stock Options Award $0 +12K +30% $0.00 52K Jul 26, 2024 Common Shares 12K $3.39 Direct
holding LEXX Stock Options 1.5K Jul 26, 2024 Common Shares 1.5K $3.00 Direct F1
holding LEXX Stock Options 6.5K Jul 26, 2024 Common Shares 5K $3.00 Direct F2
holding LEXX Stock Options 8.4K Jul 26, 2024 Common Shares 1.9K $3.00 Direct F3
holding LEXX Stock Options 11.8K Jul 26, 2024 Common Shares 3.4K $3.39 Direct
holding LEXX Stock Options 30K Jul 26, 2024 Common Shares 18.2K $1.96 Direct
holding LEXX Stock Options 35K Jul 26, 2024 Common Shares 5K $0.87 Direct
holding LEXX Stock Options 40K Jul 26, 2024 Common Shares 5K $2.36 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Repriced from $5.31 pursuant to shareholder approval received May 9, 2023
F2 Repriced from $7.08 pursuant to shareholder approval received May 9, 2023
F3 Repriced from $6.23 pursuant to shareholder approval received May 9, 2023